More and more, it seems like long-term success in chemicals and specialty materials is all about keeping an open mind toward reinvention. DuPont (NYSE:DD), for instance, is far removed from its legacy in products like gunpowder and nylon, and currently looks to advanced seed traits and nutrition as important growth markets. Likewise, DSM has moved on from coal, fertilizer and petrochemicals into areas like nutrition and biofuels.

DuPont's German cousin BASF (OTC:BASFY) is following in this path, announcing on Wednesday that it had reached an agreement to acquire Norwegian fish oil specialist Pronova for 12.50 Norwegian kroner per share, or about $845 million in enterprise value.

Credit Card Comparison: Find the credit card that is just right for you

A Cheap Deal for a High-Quality Supplement
At $845 million, BASF would be paying less than six times EV/EBITDA and only about a 4% premium to Pronova's close a day before the deal. With quite a bit of interest of late in the fish oil space, not to mention the low bid valuation, Pronova's shares are trading slightly above the bid value. Keep in mind, however, that shareholders holding more than half of Pronova's shares have agreed to the deal, though European laws give objecting minority investors more rights and leverage than in the United States.

Pronova is a leading supplier of pharmaceutical-grade fish oils - supplying the active ingredients for heart/cholesterol drug Lovaza (aka Omacor) to GlaxoSmithKline (NYSE:GSK) and Abbott Labs (NYSE:ABT). Pronova has also been actively looking to build outside of the pharmaceutical space, looking to position its fish oils into markets like clinical nutrition (parental nutrition), supplements, infant formulas and food additives - particularly those markets where especially high-grade concentrates can attract appealing pricing, and to do that they needed to turn to mergers and acquisitions.

This is not BASF's first foray into fish oil. BASF bought Equatec earlier this year, and Pronova should vault it into a leading market position in Europe and the U.S. alongside companies like Croda and DSM (which has spent about $1.6 billion over the past 18 months on Martek and Ocean Nutrition, and holds a leading share in concentrates for infant formulas).

A Deal That Says Little-to-Nothing for Amarin
One of the most controversial stocks of late in biotech has been Amarin (Nasdaq:AMRN) - an Irish biotech that has developed a highly purified omega-3 product (Vascepa) for heart disease. There has been ample debate about the sales prospects for Vascepa, including suggestions that doctors are turning away from omega-3 fatty acids/fish oil as a treatment for cholesterol and heart disease. Even more controversial is the question as to whether Amarin can secure New Chemical Entity (NCE) status from the FDA and with it, enhanced protection from potential generic competition.

Amarin has also been pegged as a company in play, with investors openly speculating on which Big Pharma may offer shareholders a lucrative buyout.

This BASF-Pronova deal, however, would seem to have little to do directly with Amarin. While it's true that Pronova supplies the key ingredient(s) for Lovaza, the drug has gone generic in Europe and will go off-patent in the U.S. in 2017. While the bulk of Pronova's revenue and profits today come from Lovaza, BASF management was quite clear that they saw the real value in the deal coming from the ongoing growth of fish oil/omega-3 fatty acids as supplements and food additives. For instance, BASF estimated that the current omega-3 concentrate market is worth about $1.1 billion today and likely to grow to over $2 billion by the end of this decade.

What's more, and I believe this is a key detail, Amarin does not produce the the ethyl-EPA that serves as the active ingredient to Vascepa. In Pronova, BASF is buying one of the largest independent producers of highly purified/concentrated omega-3 fatty acids, whereas a buyer of Amarin would primarily be acquiring the rights to market that particular formulation as a prescription treatment for heart diseases and/or high cholesterol. Consequently, I don't think Amarin investors can use the BASF-Pronova as any sort of real benchmark or comparable for a possible deal for their company.

The Bottom Line
As recent deals like Nestle's (OTC:NSRGY) bid for Pfizer's (NYSE:PFE) infant nutrition business and Reckitt Benckiser's (OTC:RBGPY) deal for Schiff Nutrition (NYSE:SHF) suggest, there is considerable interest these days in nutrition as a growth market. What's more, the M&A activity of DSM and BASF makes it sound like there's going to be considerable ongoing interest in exploiting fish oils and omega-3 fatty acids to improve the nutritional content of a wide range of food products, including infant formula.

Even with the support of major shareholders, BASF may not have Pronova wrapped up just yet. I would not be surprised to see a rival bidder step up, particularly since the valuation is not all that demanding yet. Whether a company like Bayer (OTC:BAYRY), frustrated in its attempt to buy Schiff, steps up, odds are that fish oils and omega-3 fatty acids are going to find their way into more and more clinical and consumer products in the years to come.

At the time of writing, Stephen D. Simpson did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Net Neutrality: Pros and Cons

    The fight over net neutrality has become an amazing spectacle. But at its core, it's yet another skirmish in cable television's war to remain relevant.
  2. Markets

    Why Gluten Free Is Now Big Business

    Is it essential to preserving your health, or just another diet fad? Either way, gluten-free foods have become big business.
  3. Professionals

    Chinese Slowdown Affects Iron Ore Market

    The Chinese economy's ongoing slowdown is having a major impact on iron ore demand.
  4. Personal Finance

    A Day in the Life of an Equity Research Analyst

    What does an equity research analyst do on an everyday basis?
  5. Mutual Funds & ETFs

    ETF Analysis: PowerShares S&P 500 Downside Hedged

    Find out about the PowerShares S&P 500 Downside Hedged ETF, and learn detailed information about characteristics, suitability and recommendations of it.
  6. Mutual Funds & ETFs

    ETF Analysis: ProShares Large Cap Core Plus

    Learn information about the ProShares Large Cap Core Plus ETF, and explore detailed analysis of its characteristics, suitability and recommendations.
  7. Mutual Funds & ETFs

    ETF Analysis: iShares Core Growth Allocation

    Find out about the iShares Core Growth Allocation Fund, and learn detailed information about its characteristics, suitability and recommendations.
  8. Mutual Funds & ETFs

    ETF Analysis: iShares MSCI USA Minimum Volatility

    Learn about the iShares MSCI USA Minimum Volatility exchange-traded fund, which invests in low-volatility equities traded on the U.S. stock market.
  9. Stock Analysis

    Should You Follow Millionaires into This Sector?

    Millionaire investors—and those who follow them—should take another look at the current economic situation before making any more investment decisions.
  10. Professionals

    What to do During a Market Correction

    The market has what? Here's what you should consider rather than panicking.
  1. Equity

    The value of an asset less the value of all liabilities on that ...
  2. Hard-To-Sell Asset

    An asset that is extremely difficult to dispose of either due ...
  3. Sucker Yield

    When an investor has essentially risked all of his capital for ...
  4. PT (Perseroan Terbatas)

    An acronym for Perseroan Terbatas, which is Limited Liability ...
  5. Ltd. (Limited)

    An abbreviation of "limited," Ltd. is a suffix that ...
  6. BHD (Berhad)

    The suffix Bhd. is an abbreviation of a Malay word "berhad," ...
  1. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  2. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  3. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  4. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  5. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
  6. What happens to the shares of stock purchased in a tender offer?

    The shares of stock purchased in a tender offer become the property of the purchaser. From that point forward, the purchaser, ... Read Full Answer >>

You May Also Like

Trading Center

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!